EMA Gains Political Backing for Critical Medicines Act Covering 200+ Active Substances

Supply chain vulnerability assessments for over 200 active substances on the Union critical medicines list are now a legislative reality: the European Parliament and the Council of the European Union reached provisional agreement on the Critical Medicines Act (CMA) on 12 May 2026, with EMA positioned as a central operational authority in its implementation.

For manufacturers supplying critical medicines to EU markets, the most immediate structural change is the formalised role of EMA's Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG). Under the CMA, the MSSG is mandated to conduct supply chain vulnerability assessments across the Union critical medicines list, with findings feeding directly into policy measures including strategic projects, public procurement procedures, and MSSG recommendations under the revised EU pharmaceutical legislation. The MSSG has already begun evaluating vulnerabilities in a first tranche of medicines from that list.

The CMA also codifies the standing of the Quality Innovation Expert Group (QIG), which EMA established in 2022 to support developers of innovative manufacturing technologies. For QA and regulatory leads, the QIG's reinforced mandate signals that technology-driven approaches to supply resilience will carry increasing regulatory weight during the implementation phase.

On the digital infrastructure side, EMA is expanding the European Shortages Monitoring Platform (ESMP) to enable faster, more data-consistent exchanges between industry and regulators on potential shortage signals. Plant heads and supply chain leads should treat ESMP reporting obligations as an active compliance surface, not a passive notification channel, as the platform's expanded functionality is designed to support earlier regulatory intervention.

The CMA complements, rather than replaces, the revised EU pharmaceutical legislation already in progress. Its provisions on state aid and joint procurement fall outside EMA's direct remit but are expected to influence market availability dynamics for critical medicines across Member States. EMA has confirmed it will work with the European Commission and Member States to support implementation.

The pace of MSSG vulnerability assessments across the full Union critical medicines list will be a measurable indicator of how quickly the CMA's supply resilience framework moves from political agreement to operational compliance requirement.

Source: European Medicines Agency (EMA) via ema.europa.eu, 12 May 2026. Corroborating statements issued same date by the European Commission and the Council of the European Union.